MY198715A - Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative - Google Patents

Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative

Info

Publication number
MY198715A
MY198715A MYPI2020002658A MYPI2020002658A MY198715A MY 198715 A MY198715 A MY 198715A MY PI2020002658 A MYPI2020002658 A MY PI2020002658A MY PI2020002658 A MYPI2020002658 A MY PI2020002658A MY 198715 A MY198715 A MY 198715A
Authority
MY
Malaysia
Prior art keywords
pancreatic beta
benzyloxy
hex
phenyl
beta cells
Prior art date
Application number
MYPI2020002658A
Inventor
Dae Hoon Kim
Chun Hwa Kim
Sun Hee Lee
Goeun Yang
Seung Jun Kang
Hyo Sun Choi
Original Assignee
Hyundai Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyundai Pharm Co Ltd filed Critical Hyundai Pharm Co Ltd
Publication of MY198715A publication Critical patent/MY198715A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/02—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2
    • C07D317/06—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 2 condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention provides a use of a 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative for protecting pancreatic beta cells. The 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative according to the present invention resolves a side effect in which conventionally developed agents for treating diabetes induce apoptosis of pancreatic beta cells through excitotoxic reactions, thereby causing a secondary failure in which an insulin secretory function is not controlled. The 3-(4- (benzyloxy)phenyl)hex-4-inoic acid derivative according to the present invention promotes insulin secretion only when glucose concentration is increased, thereby protecting the pancreatic beta cells from apoptosis and restoring the insulin secretory function of the pancreatic beta cells. Therefore, according to the present invention, the 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative exhibits an excellent pancreatic beta cell protection effect, when administered as a primary selective agent for diabetes and also when administered to a patient having pancreatic beta cells damaged by the use of other drugs, which are primary selection agents for diabetes and cause a secondary failure; and restores the insulin secretory function of pancreatic beta cells, thereby being useful for treating type II diabetes in a patient of which the blood glucose is not regulated in a normal manner by using an agent for promoting insulin secretion. [Fig. 12]
MYPI2020002658A 2017-12-01 2018-12-03 Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative MY198715A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762593350P 2017-12-01 2017-12-01
PCT/KR2018/015201 WO2019108046A1 (en) 2017-12-01 2018-12-03 Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative

Publications (1)

Publication Number Publication Date
MY198715A true MY198715A (en) 2023-09-19

Family

ID=66665761

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2020002658A MY198715A (en) 2017-12-01 2018-12-03 Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative

Country Status (5)

Country Link
KR (1) KR102090079B1 (en)
MY (1) MY198715A (en)
SG (1) SG11202004891PA (en)
WO (1) WO2019108046A1 (en)
ZA (1) ZA202003028B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3978485B1 (en) 2019-05-31 2026-02-11 Hyundai Pharm Co., Ltd. Novel crystal form of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative
KR102270026B1 (en) * 2020-01-31 2021-06-28 현대약품 주식회사 Quality evaluation method of (3S)-3-(4-(3-(1,4-dioxaspiro[4,5]dec-7-en-8-yl)benzyloxy)phenyl)hex-4-ynoic acid
KR102699076B1 (en) * 2021-04-01 2024-08-27 현대약품 주식회사 Novel use of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative
CN116509830A (en) * 2023-06-16 2023-08-01 桂林医学院 Application of methyl ferulic acid in preparation of insulin secretion promoting agent and synthetic agent
WO2025253265A1 (en) * 2024-06-03 2025-12-11 현대약품 주식회사 Pharmaceutical composition for preventing or treating diabetes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100354912B1 (en) * 2000-06-21 2002-10-05 박병현 Antidiabetic Amomum xanthoides extract and composition containing the extract as effective ingredient
KR20100104482A (en) * 2009-03-18 2010-09-29 한림대학교 산학협력단 Puple corn anthocyanins with excellent blood glucose control activity and efficient protective activity for diabetic loss of pancreatic beta cells
KR101121954B1 (en) * 2010-05-13 2012-03-09 아주대학교산학협력단 Composition for preventing or treating diabetes comprising 1,2,3-Benzentricarboxylic acid
IN2013CN01340A (en) * 2010-07-23 2015-08-07 Connexios Life Sciences Pvt Ltd
KR20140097837A (en) * 2013-01-30 2014-08-07 부산대학교 산학협력단 PADINA ARBORESCENS EXTRACT FOR PROMOTING INSULIN SECRETION AND PROTECTING PANCREATIC β CELL
KR101569522B1 (en) * 2013-04-18 2015-11-17 현대약품 주식회사 Novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, preparation method thereof, and pharmaceutical composition for use in preventing or treating metabolic diseases containing the same as an active ingredient
EP3207928B1 (en) * 2014-10-17 2021-03-10 Hyundai Pharm Co., Ltd. Composite preparation, containing novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ingredient, for preventing or treating metabolic diseases

Also Published As

Publication number Publication date
KR20190141007A (en) 2019-12-20
ZA202003028B (en) 2021-08-25
SG11202004891PA (en) 2020-06-29
WO2019108046A1 (en) 2019-06-06
KR102090079B1 (en) 2020-03-17

Similar Documents

Publication Publication Date Title
JOP20250198A1 (en) GIP/GLP1 Common Auxiliary Vehicles
JOP20220024A1 (en) Gipr-agonist compounds
EA201270666A1 (en) COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR REDUCING URIC ACID LEVEL
MX2010004503A (en) Oxadiazolidinedione compound.
EA201892383A1 (en) COMPOSITION FOR THE TREATMENT OF DIABETES OR DIAZHIRENA, CONTAINING ANALOGUE OF OXYNTHOMODULIN
JOP20220311A1 (en) Long-acting acyl-treated insulin compounds
ECSP22056585A (en) ENGINEERED VARIANTS OF ACID ALPHA-GLUCOSIDASE
JOP20220293A1 (en) Antibodies against GLP1R and methods of their use
MA40873B1 (en) Trifluoromethylated alcohols as roryt modulators
PY22104936A (en) "BCKDK INHIBITORS AND/OR DEGRADERS"
WO2020109526A3 (en) Oxyntomodulin peptide analog formulations
MX357071B (en) Method of treating diabetes using non-glycosylated apolipoprotein a-iv.
Griffiths et al. Contemporary management of cytomegalovirus infection in transplant recipients: guidelines from an IHMF workshop, 2007.
MX2022008681A (en) Combinational therapy comprising glp-1 and/or glp-1 analogs, and insulin and/or insulin analogs.
EA201391063A1 (en) APOLIPOPROTEIN A-IV AS ANTIDIABETIC PEPTIDE
Muscogiuri et al. Albiglutide for the treatment of type 2 diabetes.
WO2014193832A3 (en) Glucagon-like peptide 1 (glp-1) receptor modulators and uses thereof in regulating blood glucose levels
Creisson et al. Captopril/hydrochlorothiazide combination in elderly patients with mild-moderate hypertension. A double-blind, randomized, placebo-controlled study.
EP4324522A3 (en) Methods of treating fabry patients having renal impairment
MXPA02012315A (en) Pharmaceutical compound containing silimarine and carbopol, fabrication process and its use as regenerator of pancreatic tissue and cells of endogenous secretion damaged by diabetes mellitus.
BRPI0508509A (en) methods for altering insulin secretion
MX2024002534A (en) COMPOSITIONS AND METHODS FOR PROPAGATING INSULIN AND GLUCAGON-SECRETARY CELLS FROM TYPE 1 DIABETIC PANCREATIC TISSUE AND THERAPEUTIC USES THEREOF.
Gatskikh et al. Effectiveness of cytoflavin for the correction of cognitive impairments in patients with type 2 diabetes mellitus
WO2022271944A3 (en) Compositions and methods for treatment of gaucher disease
De Mestier et al. Dramatic efficacy of chemotherapy with 5-fluorouracil and dacarbazine in a patient with metastatic glucagonoma and cardiac insufficiency